Drug Trial Radar · NCT04798209
A Study to Examine the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Jun 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
70
Actual
Start
Jan 29, 2021
Primary completion
Jan 26, 2022
Study completion May 21, 2022
Sponsor
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.
Conditions
- Healthy
Interventions
ACT-777991 (SAD)Drug
ACT-777991 administered as hard capsules for oral use.
ACT-777991 (MAD)Drug
ACT-777991 administered as hard capsules for oral use, once daily.
Placebo (SAD)Drug
ACT-777991 matching placebo administered as hard capsules for oral use.
Placebo (MAD)Drug
Matching placebo administered as hard capsules for oral use, once daily.
14C-ACT-777991 microtracer (SAD - Absolute Bioavailability)Drug
Single dose of 14C-ACT-777991 microtracer, administered intravenously.
Microtracer matching placebo (SAD - Absolute Bioavailability)Drug
Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
14C-ACT-777991 microtracer (MAD - ADME)Drug
Single dose of 14C-ACT-777991 microtracer, oral solution..
Microtracer matching placebo (MAD - ADME)Drug
Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events.Time frame: From first dose on Day 1 to Day 4 after the last dose was administered
Locations
1 site in 1 country. Site status is shown where the registry gives one.
QPS Netherlands B.V.
Groningen, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.